Synapse - David Hyman

Results (31)

Real-time genomic profiling of pancreatic ductal adenocarcinoma: Potential actionability and correlation with clinical phenotype

Journal Article

Lowery, M. A.; Jordan, E. J.; Basturk, O.; Ptashkin, R. N.; Zehir, A.; Berger, M. F.; Leach, T.; Herbst, B.; Askan, G.; Maynard, H.; more...
Clinical Cancer Research (2017)

Fulltext@MSK | Save

Identification of potentially actionable molecular alterations in advanced hepatocellular carcinoma (HCC)

Meeting Abstract

Harding, J. J.; Heins, Z. J.; Connell, L. C.; Soumerai, T.; Kemeny, N. E.; Jarnagin, W. R.; O'Reilly, E. M.; DeMatteo, R. P.; D'Angelica, M. I.; Lowery, M. A.; more...
Journal of Clinical Oncology (2016)

Fulltext@MSK | Save

Vemurafenib in patients with Erdheim-Chester disease (ECD) and Langerhans cell histiocytosis (LCH) harboring BRAF(V600) mutations: A cohort of the histology-independent VE-BASKET study

Meeting Abstract

Diamond, E. L.; Subbiah, V.; Lockhart, C.; Blay, J. Y.; Faris, J. E.; Puzanov, I.; Chau, I.; Raje, N. S.; Wolf, J. S.; Erinjeri, J.; more...
Blood (2016)

Fulltext@MSK | Save

Beyond the dose-limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program

Journal Article

Drilon, A.; Eaton, A. A.; Schindler, K.; Gounder, M. M.; Spriggs, D. R.; Harris, P.; Ivy, S. P.; Iasonos, A.; Lacouture, M. E.; Hyman, D. M.
Cancer (2016)

Fulltext@MSK | Save

Diverse and targetable kinase alterations drive histiocytic neoplasms

Meeting Abstract

Durham, B. H.; Diamond, E. L.; Haroche, J.; Yao, Z.; Ma, J.; Parikh, S. A.; Choi, J.; Kim, E.; Cohen-Aubart, F.; Lee, S. C. W.; more...
Blood (2015)

Fulltext@MSK | Save

Diverse and targetable kinase alterations drive histiocytic neoplasms

Journal Article

Diamond, E. L.; Durham, B. H.; Haroche, J.; Yao, Z.; Ma, J.; Parikh, S. A.; Wang, Z.; Choi, J.; Kim, E.; Cohen-Aubart, F.; more...
Cancer Discovery (2015)

Fulltext@MSK | Save

Diverse kinase mutations and fusions drive non-Langerhans cell histiocytoses

Meeting Abstract

Durham, B.; Diamond, E.; Yao, Z.; Ma, J.; Choi, J.; Kim, E.; Lee, S.; Gao, Y.; Micol, J. B.; Campbell, P.; more...
Pediatric Blood and Cancer (2015)

Fulltext@MSK | Save

Dermatologic toxicities of 3,517 solid tumor patients on phase I clinical trials of the National Institutes of Health Cancer Therapy Evaluation Program (CTEP)

Meeting Abstract

Drilon, A. E.; Eaton, A.; Schindler, K.; Gounder, M. M.; Smith, G. L.; Vulih, D.; Harris, P. J.; Spriggs, D. R.; Ivy, P.; Iasonos, A.; more...
Journal of Clinical Oncology (2015)

Fulltext@MSK | Save

Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors

Journal Article

Hyman, D. M.; Snyder, A. E.; Carvajal, R. D.; Gerecitano, J. F.; Voss, M. H.; Ho, A. L.; Konner, J.; Winkelmann, J. L.; Stasi, M. A.; Monson, K. R.; more...
Cancer Chemotherapy and Pharmacology (2015)

Fulltext@MSK | Save

Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders

Journal Article

Hyman, D. M.; Diamond, E. L.; Vibat, C. R. T.; Hassaine, L.; Poole, J. C.; Patel, M.; Holley, V. R.; Cabrilo, G.; Lu, T. T.; Arcila, M. E.; more...
Cancer Discovery (2015)

Fulltext@MSK | Save